Clinical Trial Update: Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combined inhibition of DPP-4 (CD26) and aminopeptidase N (CD13) for psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• APN/CD13 inhibitor (Aminopeptidase N (APN) inhibitor)
• DPIV/CD26 inhibitor (Dipeptidyl peptidase IV (DPP-4) inhibitor)

Snippet

Sponsor: Immune Technologies & Medicine GmbH | Conditions: Psoriasis | Phase 2 | Status: UNKNOWN